Platinum pathway

Pharmacogenetics and Genomics

Volumn 19, Issue 7, 2009, Pages 563-564

  Marsh, Sharon ^a   McLeod, Howard ^b   Dolan, Eileen ^c   Shukla, Sunita J ^c   Rabik, Cara A ^c   Gong, Li ^d   Hernandez Boussard, Tina ^d   Lou, Xing Jian ^d   Klein, Teri E ^d   Altman, Russ B ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MEMBRANE PROTEIN; MENKES PROTEIN; OXALIPLATIN; PLATINUM; WILSON DISEASE PROTEIN; XERODERMA PIGMENTOSUM GROUP A PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN;

CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL DIVISION; CELL GROWTH; DNA ADDUCT; DNA HELIX; DRUG MECHANISM; PRIORITY JOURNAL; SHORT SURVEY; TRANS GOLGI NETWORK; ARTICLE; DNA REPAIR; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC NETWORKS AND PATHWAYS; PLATINUM; TRANS-GOLGI NETWORK;

EID: 67651213976     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832e0ed7     Document Type: Short Survey

References (29)

1. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-584.
2. Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov 2006; 1:1-22.
3. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Perez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem 2007; 7:3-18.
4. Abu-Surrah AS. Development and current status of unconventional platinum anticancer complexes. Mini Rev Med Chem 2007; 7:203-211.
5. Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS, Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 2003; 9:5853-5859.
6. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 2002; 62:6559-6565.
7. Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol 2002; 62:1154-1159.
8. Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 2004; 10:1691-1697.
9. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003; 121:172-176.
10. Ceckova M, Vackova Z, Radilova H, Libra A, Buncek M, Staud F. Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro 2008; 22:1846-1852.
11. Pasheva EA, Ugrinova I, Spassovska NC, Pashev IG. The binding affinity of HMG1 protein to DNA modified by cis-platin and its analogs correlates with their antitumor activity. Int J Biochem Cell Biol 2002; 34:87-92.
12. Chaney SG, Vaisman A. Specificity of platinum-DNA adduct repair. J Inorg Biochem 1999; 77:71-81.
13. Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 2003; 39:112-119.
14. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61:8654-8658.
15. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-2601.
16. Stoehlmacher J, Ghaderi V, Iobal S, Groshen S, Tsao-Wei D, Park D, Lenz HJ. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res 2001; 21:3075-3079.
17. Van der Straaten T, Kweekel D, Tiller M, Bogaartz J, Guchelaar HJ. Multiplex pyrosequencing of two polymorphisms in DNA repair gene XRCC1. J Mol Diagn 2006; 8:444-448.
18. Sakano S, Wada T, Matsumoto H, Sugiyama S, Inoue R, Eguchi S, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006; 95:561-570.
19. Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, et al. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 2009. [Epub ahead of print]
20. Bhattacharya R, Beck DJ. Survival and SOS induction in cisplatin-treated Escherichia coli deficient in Pol II, RecBCD and RecFOR functions. DNA Repair (Amst) 2002; 1:955-966.
21. Vaisman A, Masutani C, Hanaoka F, Chaney SG. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase beta. Biochemistry 2000; 39:4575-4580. (Pubitemid 30225320)
22. Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94:936-942.
23. Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003; 8:156-161.
24. Watanabe K, Yagi T. Expression of myeloperoxidase in the inner ear of cisplatin-treated guinea pigs. Anticancer Drugs 2000; 11:727-730.
25. Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002; 21:1119-1124.
26. Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 2000; 85:777-781.
27. Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, et al. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs 2000; 11:639-643.
28. Okcu MF, Selvan M, Wang LE, Stout L, Erana R, Airewele G, et al. Glutathione S-transferase polymorphisms and survival in primary malignant glioma. Clin Cancer Res 2004; 10:2618-2625.
29. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, et al. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 2006; 106:441-447.